Full-Time

Director – Packaging Development

Posted on 6/13/2026

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

Compensation Overview

$166.8k - $228.8k/yr

+ Bonus + Commission + Equity

Columbia, MD, USA

In Person

Category
Biology & Biotech (1)
Responsibilities
  • Manage the design, development, and qualification of packages and packaging systems for sterile and non-sterile medical devices at Integra Lifesciences.
  • Articulate and drive the overall division-wide packaging strategy and develop the associated Standard Operating Procedures (SOPs) and best practices to ensure success and align to current regulations and business strategies.
  • Establish and oversee timelines, budget estimates, and resource requirements for package development, sustaining and continuous improvement projects and drive the projects to successful completion.
  • Mentor the Tissue Technologies R&D Packaging Engineering team members and provide project direction, prioritization, and technical oversight to ensure successful implementation of packaging strategy in support of product leadership goals.
  • Support the conceptualization, initiation, development and implementation of new packages and processes including design generation, prototyping, consumer acceptance testing, engineering specifications, verification and validation, and technology transfer.
  • Identify and investigate industry best practices and implementation improvements as appropriate.
  • Demonstrate technical expertise on packaging, materials, and processes along with the ability to communicate that knowledge to internal and external partners.
  • Oversee the overall operation of the Integra Lifesciences Columbia, Md site package testing laboratory including sample preparation, test execution and reporting.
  • Prepare and maintaining the departmental policies, procedures, and manuals.
  • Investigate design changes and failures, product complaints, and non-conformances, report findings and recommendations in company systems for corrective and preventive action.
  • Review Failure Mode Effects Analysis (FMEA) and risk assessments for products and processes.
  • Perform process validations of new and modified designs and processes.
  • Collaborate with Quality to ensure compliance to appropriate ISO/FDA regulations for the design, testing, documentation, and manufacturing of the company’s products.
  • Interface with Manufacturing, Quality, Regulatory, Research & Development, Sales, Marketing, and outside vendors to accomplish assigned tasks.
  • Perform other duties as assigned.
Desired Qualifications
  • Minimum of a bachelor’s degree in Packaging Engineering or other engineering disciplines or possess the equivalent combination of education and experience. A master’s degree in Packaging Engineering or other engineering disciplines is preferred.
  • Minimum of 15 years of experience developing and validating packaging systems for medical devices.
  • Expert knowledge of the U.S. and International standards governing the design, development, testing, and manufacture of medical devices, particularly ISO 11607, ISO 13485 well as ASTM and ISTA test methods and practices.
  • Expert knowledge of U.S. FDA, cGMP, and ISO requirements for the design, validation, manufacturing processes, secondary operations, and assembly of packaging systems
  • Ability to drive projects with tight timelines and drive them to successful completion.
  • Excellent verbal and written communication skills; ability to lead meetings and effectively present to a group.
  • Demonstrate effective time management and verbal and written communication.
  • Critical thinking and problem solving to develop solutions
  • Knowledge of gamma, ETO, and e-beam sterilization methods
  • Proficient in computer software programs such as SolidWorks, ArtisoCAD, and barcode generation software (Bartender, Loftware, etc.).
  • Proficient PC skills (MS Word, MS Excel, MS Project, MS Visio).

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Your Connections

People at Integra LifeSciences who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $391.9 million, beating expectations and rising organically.
  • Adjusted EPS guidance increased to $2.40-$2.50 after stronger margins and supply execution.
  • Management targets roughly $200 million operating cash flow and reduced tariff pressure.

What critics are saying

  • Recurring quality issues continue to disrupt availability, margins, and investor confidence.
  • Net debt around $1.6 billion limits flexibility until deleveraging progresses materially.
  • SurgiMend relaunch execution remains fragile if Braintree ramp, inventory, or QA slips.

What makes Integra LifeSciences unique

  • Integra combines neurosurgery, wound reconstruction, and specialty surgical products.
  • Stuart Essig returned as CEO in 2026 to accelerate operational recovery.
  • Braintree reactivation supports SurgiMend’s planned fourth-quarter 2026 relaunch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Feb 26th, 2026
Integra LifeSciences sees 0.7% organic revenue decline in 2025, guides to $1.66B–1.7B for 2026

Integra LifeSciences reported Q4 revenue of $435 million and adjusted earnings per share above guidance midpoint, but faces headwinds in 2025. Full-year revenue reached $1.635 billion with 0.7% organic decline, whilst gross margin fell 260 basis points to 61.9% due to tariffs, quality remediation and supply constraints. For 2026, the company guided revenue of $1.66 billion to $1.7 billion and adjusted EPS of $2.30 to $2.40, excluding potential new tariff impacts. Management expects operating cash flow exceeding $200 million and plans to reduce leverage from 4.5 times to 2.5–3.5 times by year-end. The company highlighted operational improvements including a new operating model, supply-chain resilience and early relaunches of PriMatrix and DuraRepair. A Braintree facility launching by June should support SurgiMend's Q4 2026 return.

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences shares fall 3.5% on weak Q1 revenue forecast despite Q4 beat

Integra LifeSciences shares fell 3.5% after the medical device company issued weak revenue guidance for the first quarter and reported a significant drop in profitability. The company forecast first-quarter revenue of $382.5 million, 2.8% below analyst expectations. Whilst fourth-quarter revenue of $434.9 million and adjusted earnings per share of $0.83 beat expectations, underlying metrics showed deterioration. Revenue declined 1.7% year-over-year, operating margin fell sharply to 5.3% from 14.5% the previous year, and free cash flow was negative $5.4 million compared to positive $21.14 million a year ago. The combination of weak outlook and deteriorating profitability overshadowed the headline beats. Shares are down 6.9% year-to-date and trading 53.3% below their 52-week high.

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences Q4 sales beat estimates but Q1 guidance misses by 2.8%

Integra LifeSciences reported Q4 2025 revenue of $434.9 million, beating analyst estimates by 1% but declining 1.7% year on year. The medical device company's adjusted earnings per share of $0.83 exceeded expectations by 3.7%. However, the company's Q1 2026 revenue guidance of $382.5 million fell 2.8% below analyst estimates. Operating margin dropped to 5.3% from 14.5% in the prior year quarter, whilst free cash flow turned negative at -$5.4 million. Founded in 1989, Integra develops medical technologies for neurosurgery, wound care and surgical reconstruction. The company has struggled with tepid growth, recording just 3.6% compound annual revenue growth over five years. Its organic revenue rose 2.5% year on year in the quarter.

Yahoo Finance
Feb 25th, 2026
Integra LifeSciences to report Q4 earnings tomorrow amid 2.7% revenue decline forecast

Medical device company Integra LifeSciences will report earnings tomorrow, with analysts expecting revenue to decline 2.7% year on year, reversing an 11.5% increase from the same quarter last year. The company missed revenue expectations last quarter, reporting $402.1 million in revenues, up 5.6% year on year. It also significantly missed revenue guidance for the following quarter. Integra has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have generally reconfirmed their estimates over the last 30 days. Integra's shares are up 5.7% over the past month, outperforming the healthcare equipment segment's 1.9% decline. The stock currently trades at $11.70 against an average analyst price target of $15.50.

DECCO, Inc.
Nov 13th, 2025
DECCO Recognized for "Excellence in Construction"

DECCO recognized for "Excellence in Construction" WOBURN, MA - The Massachusetts Chapter of Associated Builders and Contractors (ABC MA) congratulates DECCO for earning an Eagle Award at the 33rd annual Excellence in Construction Awards for their outstanding work on Integra Life Sciences' Project Revere. Nearly 250 ABC members gathered at the Four Points by Sheraton Hotel in Norwood on November 6th to recognize and celebrate the very best construction projects their companies have to offer. This year's applicant pool was particularly competitive, with each winner selected for the high standards of craftsmanship, safety and quality delivered by talented merit shop workers using the efficient merit shop approach. "We are proud to recognize the outstanding work of our member contractors through the ABC Excellence in Construction Awards," said ABC MA President Greg Beeman. "The winning contractors maintained a constant focus on meeting their clients' needs and set a high bar for craftsmanship, quality and safety." The Eagle Award DECCO won for Project Revere is the pinnacle of achievement. It recognizes overall excellence in project execution, craftsmanship, safety, innovative elements and challenges, and client satisfaction. The Massachusetts Chapter of Associated Builders and Contractors is the largest construction trade association in the Commonwealth, representing nearly 500 local general contractor, subcontractor, supplier and associate members that employ over 20,000 workers throughout Massachusetts.